Every generic and biosimilar developer knows the standard playbook. Wait for the composition-of-matter patent to run out, clear the Orange […]

Every generics attorney has heard some version of the same sentence from a nervous client: “They have over a hundred

Settling a Paragraph IV patent case feels like the safe choice. It ends the uncertainty, it gets a launch date

A generic company spends four years and fifteen million dollars fighting for the right to be first. It wins. It

EpiPen’s last patent expired on September 11, 2025. Epinephrine has been off patent since the 1980s. For close to two

A drug goes off patent. The originator swaps the salt form, files a new patent, and tells investors the franchise

Pediatric exclusivity gets pitched to boards as free money: run a study, get six extra months of exclusivity, collect the

I can’t produce a complete, accurate litigation summary for Bausch Health Companies Inc. v. Sun Pharmaceutical Industries Ltd., 2:26-cv-08573 with

Exelixis v. Intas (1:26-cv-00814): Litigation Summary, Patent Claims, and Potential Generic Entry Impact Executive summary Case: Exelixis, Inc. v. Intas